Tudor Investment Corp ET AL Buys Shares of 32,571 Avanos Medical, Inc. (NYSE:AVNS)

Tudor Investment Corp ET AL purchased a new position in Avanos Medical, Inc. (NYSE:AVNS - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 32,571 shares of the company's stock, valued at approximately $519,000. Tudor Investment Corp ET AL owned about 0.07% of Avanos Medical as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Aquatic Capital Management LLC increased its holdings in shares of Avanos Medical by 86.6% during the fourth quarter. Aquatic Capital Management LLC now owns 21,274 shares of the company's stock valued at $339,000 after acquiring an additional 9,874 shares in the last quarter. T. Rowe Price Investment Management Inc. grew its position in Avanos Medical by 27.2% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,011,312 shares of the company's stock valued at $47,941,000 after acquiring an additional 644,267 shares in the last quarter. Tower Research Capital LLC TRC grew its position in shares of Avanos Medical by 493.3% during the fourth quarter. Tower Research Capital LLC TRC now owns 8,075 shares of the company's stock worth $129,000 after buying an additional 6,714 shares in the last quarter. First Trust Advisors LP purchased a new stake in Avanos Medical during the fourth quarter worth approximately $1,234,000. Finally, CANADA LIFE ASSURANCE Co lifted its stake in Avanos Medical by 22.1% in the fourth quarter. CANADA LIFE ASSURANCE Co now owns 75,341 shares of the company's stock valued at $1,198,000 after buying an additional 13,634 shares during the last quarter. 95.17% of the stock is currently owned by institutional investors.

Avanos Medical Trading Up 3.4%

NYSE AVNS traded up $0.43 during trading hours on Monday, hitting $13.08. 545,910 shares of the company's stock were exchanged, compared to its average volume of 349,151. The business's 50 day moving average is $13.43 and its 200-day moving average is $15.99. Avanos Medical, Inc. has a 12-month low of $11.84 and a 12-month high of $25.36. The firm has a market capitalization of $601.81 million, a P/E ratio of 38.48 and a beta of 1.13. The company has a debt-to-equity ratio of 0.12, a quick ratio of 1.46 and a current ratio of 2.22.

Avanos Medical (NYSE:AVNS - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported $0.26 EPS for the quarter, topping analysts' consensus estimates of $0.19 by $0.07. The company had revenue of $167.50 million for the quarter, compared to the consensus estimate of $161.75 million. Avanos Medical had a return on equity of 4.70% and a net margin of 2.30%. The company's quarterly revenue was up .8% compared to the same quarter last year. During the same period last year, the business posted $0.22 EPS. As a group, analysts anticipate that Avanos Medical, Inc. will post 1.32 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Separately, StockNews.com upgraded Avanos Medical from a "hold" rating to a "buy" rating in a research report on Wednesday, March 19th.

Insider Transactions at Avanos Medical

In other Avanos Medical news, SVP Kerr Holbrook sold 7,000 shares of Avanos Medical stock in a transaction on Thursday, March 6th. The stock was sold at an average price of $15.25, for a total transaction of $106,750.00. Following the sale, the senior vice president now owns 82,047 shares of the company's stock, valued at $1,251,216.75. The trade was a 7.86% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders own 2.64% of the company's stock.

Avanos Medical Profile

Avanos Medical, Inc, a medical technology company, offers medical device solutions in North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin America. It offers a portfolio of chronic care products that include digestive health products, such as Mic-Key enteral feeding tubes, Corpak patient feeding solutions, and NeoMed neonatal and pediatric feeding solutions.